openPR Logo
Press release

Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

04-04-2019 01:50 PM CET | Health & Medicine

Press release from: Pharma Proff

Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline

Hospital acquired pneumonia (HAP) is a lung infection that occurs during hospital stay. HAP can spread via health care workers, who may pass germs from their hands or clothes from one patient to another.

Download the sample report @

This is why hand-washing, wearing gowns, and using other safety measures is so important in hospitals and other healthcare settings. It has been observed that HAP may develop at least 48 hours after hospital admission.

Get the detailed analysis @

There are several risk factors associated with HAP including alcohol consumption, major surgery, weak immune system, chronic lung disease, and swallowing problems.

Make enquiry before purchase @

The disease can be treated with antibiotics and can be controlled by taking hygiene prevention during a hospital stay. Arsanis Inc. is in the process of developing ASN100 as a monoclonal antibody for the treatment of HAP. Some of the companies involved in HAP pipeline are Allecra Therapeutics GmbH and Nabriva Therapeutics plc among others.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments here

News-ID: 1688252 • Views: 284

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for HAP

Hydroxyapatite Hap Market, Industry Share, Trends, Growth, Future Prospects, For …
The Hydroxyapatite (HAp) market is expected to grow by 6.5% CAGR from 2019 to 2025, growing from $2.2 billion in 2019 to $3.1 billion in 2025. Hydroxyapatite (HAp) is a mineral present in the bones and hard tissues of humans and animals. The micro-sized hydroxyapatite (HAp) can be designed using nanotechnology applicable to orthopedic surgery and drug delivery systems. It is mainly used for various bone graft methods, and is also
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2020 | EnBiotix, Helperb …
The Hospital Acquired Pneumonia (HAP) - Pipeline Market to witnessed good recovery in growth post first half of 2020 and is projected coverup market sizing during the forecast period (2021-2026). The assessment provides a 360° view and insights - outlining the key outcomes of the Hospital Acquired Pneumonia (HAP) - Pipeline market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players
2025 Hydroxyapatite Market (HAp) Developing CAGR During the Forecast Report | CA …
Get sample at . Hydroxyapatite Market (HAp) 2025 research report has been prepared based on a deep market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this Global market. Hydroxyapatite (HAp) is a calcium phosphate similar to the human hard tissues in morphology and composition. Particularly, it
Global Hydroxyapatite (HAp) Market to Grow at a CAGR over 6.11% from 2018 to 202 … launched a study titled “Global Hydroxyapatite (HAp) Market by Type (Nano-Sized, Micro-Sized, Greater than Micrometers), Application (Orthopedic, Dental Care, Plastic Surgery), Region (North America, Europe, Asia Pacific, South America and Middle East and Africa)” and Global Forecast 2018-2025. The global hydroxyapatite (HAp) market is expected to grow from USD 2.16 Billion in 2017 to USD 3.47 Billion by 2025 at a CAGR of 6.12% during the forecast period from 2018-2025.
Global Hospital-Acquired Pneumonia (HAP) Drugs Market 2019 - Teva Pharmaceutical …
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms.
Global Hospital-acquired Pneumonia (HAP) Drugs Market Outlook 2017-2021
The study of Hospital-acquired Pneumonia (HAP) Drugs Market in UK 2017-2021 industry is very important to enhance business productivity and for the study of market forecast. This New Report presented by Orbis Reseach contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Hospital-acquired Pneumonia (HAP) Drugs is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of